Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28822576

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2017 Oct 21
First author
Schachter J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Oct 21;390(10105):1816-1817. doi: 10.1016/S0140-6736(17)31816-0.
    note
    Source null
    related pmid
    28822577
    relationship
    Comment in

Authors and identifiers

  1. name
    Schachter J
    type
    Author
  2. name
    Ribas A
    type
    Author
  3. name
    Long GV
    type
    Author
  4. name
    Arance A
    type
    Author
  5. name
    Grob JJ
    type
    Author
  6. name
    Mortier L
    type
    Author
  7. name
    Daud A
    type
    Author
  8. name
    Carlino MS
    type
    Author
  9. name
    McNeil C
    type
    Author
  10. name
    Lotem M
    type
    Author
  11. name
    Larkin J
    type
    Author
  12. name
    Lorigan P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Schachter J
    type
    Author
  2. name
    Ribas A
    type
    Author
  3. name
    Long GV
    type
    Author
  4. name
    Arance A
    type
    Author
  5. name
    Grob JJ
    type
    Author
  6. name
    Mortier L
    type
    Author
  7. name
    Daud A
    type
    Author
  8. name
    Carlino MS
    type
    Author
  9. name
    McNeil C
    type
    Author
  10. name
    Lotem M
    type
    Author
  11. name
    Larkin J
    type
    Author
  12. name
    Lorigan P
    type
    Author
bibliography ids
  1. nci-bib-fe145bc2958d07a9b5043497
book metadata
content sha256
1ea85cb119d83b5b2a4e1260846b9e0629dd7774e3d47607afc09f68eaf833a7
document type
citation
dois
  1. 10.1016/S0140-6736(17)31601-X
electronic publication date
display
2017 Aug 16
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28822576
immutable id
pubmed:28822576@1ea85cb119d83b5b2a4e1260846b9e0629dd7774e3d47607afc09f68eaf833a7
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10105
name
Lancet (London, England)
nlm unique id
2985213R
pages
1853-1862
volume
390
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Oct 21;390(10105):1816-1817. doi: 10.1016/S0140-6736(17)31816-0.
    note
    Source null
    related pmid
    28822577
    relationship
    Comment in
outcomes validated
false
pmid
28822576
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
b8223674d4319372c8c398cab206ea39f86fa64ed38226bd243d0f41683df7e4
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Oct 21
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28822576/
title
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Preserved source evidence · Not medical advice